Industries > Pharma > Hepatitis Drugs and Vaccines: World Market 2013-2023

Hepatitis Drugs and Vaccines: World Market 2013-2023

PUBLISHED: 21 June 2013
PAGES: 197
PRODUCT CODE:
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: N/A Categories: ,

Your guide to sales outlooks and R&D for hepatitis treatments

Where are hepatitis medicines going? Visiongain's updated report predicts revenues there from 2013 to 2023. It also explains trends in that business and technology – with prospects and opportunities – to help your work.

In that study you gain sales forecasts at overall world market, submarket, product, and national level. See what's happening. Also discover what has most growth potential.

Read on, then, to explore that industry and see what its future market could be worth.

Forecasts to 2023 and other analyses show you commercial potentials

Besides revenue forecasting, our new work shows historical data, growth rates, and market shares. You discover original quantitative and qualitative analysis, seeing business outlooks and research developments (R&D). You also get 77 tables, 66 charts, and an interview.

Is finding data for anti-hepatitis products a challenge? Avoid falling behind. You can now stay ahead in knowledge, benefiting your research, analyses, and decisions. Also save time.

There you investigate the future of hepatitis medicine. You discover what's happening and see where the money lies. Finding that antiviral data just got easier.

Anyhow, the following sections show what you get in our new research and analysis.

Discover prospects for the world market and submarkets

Our new report shows revenue to 2023 for the overall world market. It also shows you individual forecasts of four hepatitis treatment submarkets:
• Oral antivirals
• Interferons
• Vaccines
• Other agents.

How will the hepatitis drugs and vaccines market expand? Which parts will most prosper? There you assess potential for sales and revenue growth.

Also our study discusses what stimulates and restrains that market. That analysis helps you identify potential and find ways for your business to benefit.

You also find revenue predictions for brands.

See forecasts for 10 leading anti-hepatitis products

How will those antiviral brands perform to 2023 at world level? Our study forecasts individual revenues of 10 top products:
• Baraclude
• Zeffix
• Hepsera
• Viread
• Tyzeka
• Engerix-B/Havrix/Twinrix/Fendrix
• Pegasys
• Incivek
• PegIntron
• Victrelis.

There you discover how high sales can go, to 2023, finding products and years with highest predicted growth and revenues. Also you compare competitors. You see what's happening, then, understanding trends, competition, challenges, and opportunities.

Our report also divides its overall world forecast into geographical regions.

What prospects for regions and countries?

Developments worldwide expand the hepatitis products market, especially rising demand for medicines in emerging countries. China, India, Russia, and Brazil underpin revenue growth.

In developed and developing countries, opportunities for pharmaceutical companies will occur from 2013 to 2023. See where and how.

Our analyses show you individual revenue forecasts to 2023 for 11 national markets:
• United States (US)
• Japan
• EU leaders – Germany, France, the UK, Italy, and Spain (EU5)
• BRIC countries – Brazil, Russia, India, and China.

There you discover progress and outlooks. In particular, drug and vaccine launches from 2013 to 2023 will change medical prescribing and the commercial landscape. See how.

Research and development – assess innovation, trends, and possibilities

What about R&D – pipelines for new drugs and vaccines? You assess trends there, including these:
• Cyclophilin inhibition
• Protease inhibition
• All-oral agents
• Agents with potential roles in hep-C/HIV co-infection
• Nucleoside and non-nucleoside polymerase inhibition
• Therapeutic vaccines
• Combination regimens.

R&D for hepatitis medicine holds strength, variety, and promise. You assess innovations there, hearing about developments and finding their significance. Discover progress.

For large companies and specialty pharma firms there exist many opportunities. Our study explains, discussing progress to help your work. See, then, what the future holds.

Prominent companies and 2017 market value

What happens next? From 2013, new treatments hold great potential for investment, technological advances and high revenues. Our report predicts the world market for anti-hepatitis drugs and vaccines will reach $15.25bn in 2017, and expand further to 2023.

Our work shows you what activities, technologies, and organisations there hold potential. Its analyses cover prominent companies, including these:
• Roche
• GSK
• Bristol-Myers Squibb
• Merck & Co.
• Vertex Pharmaceuticals
• Gilead Sciences
• Novartis.

Prospects for R&D are strong, and from 2013 there will arise many opportunities. Our analysis shows you possibilities, helping you stay ahead.

Nine ways Hepatitis Drugs and Vaccines: World Market 2013-2023 helps you

To sum up, our investigation gives you the following knowledge:
• Revenue to 2023 of the world market for anti-hepatitis products – discover that industry's overall sales potential
• Revenues to 2023 for 4 world-level submarkets – investigate the potential of its components, finding the most promising places for investments and revenues
• Revenues to 2023 for 10 products – find sales outlooks for top brands, seeing how they can compete and succeed
• Forecasts to 2023 for 11 national markets in the Americas, Europe, and Asia – discover the best countries for revenues and potential growth
• Assessments of 11 companies – hear about participants' activities, capabilities, results, and outlooks
• Review of R&D – explore progress in research and development, finding technological and medical possibilities
• Competition and opportunities – investigate what shapes that market's future, including ways to develop business
• Analysis of what stimulates and restrains that industry and market – assess challenges and strengths, helping you compete and get advantages
• Prospects for established competitors and firms seeking to enter that sector – explore needs, practices and outlooks for future success.

You gain information found nowhere else

That work gives independent analysis. You receive business intelligence found only in our report, seeing where prospects are most rewarding.

With our study you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses, and decisions. Also see how you can save time and get recognition for commercial insight.

Assess the potential of those antiviral agents now, seeing what you can gain.

Hepatitis medicine – see commercial prospects from 2013 by ordering now

Our new study lets you find data, trends, opportunities, and sales predictions for hepatitis prevention and treatment. Avoid missing out – please order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

To view free sample pages of this report please click here

Download sample pages

Complete the form below to download your free sample pages for Hepatitis Drugs and Vaccines: World Market 2013-2023


Download sample pages

Complete the form below to download your free sample pages for Hepatitis Drugs and Vaccines: World Market 2013-2023


Latest Pharma news

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021

READ

Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021

READ

Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021

READ

Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2021-2031

Digital innovation in clinical trials and renewed focus on home production will ensure a high growth market for supply chain optimisation.

12 July 2021

READ

Categories